Novo Nordisk LIFE In Vivo Pharmacology Centre (LIFEPHARM)
ORIGINAL ARTICLE
Local and systemic effects of co-stimulatory blockade using cytotoxic T lymphocyte antigen-4-immunoglobulin in dinitrofluorobenzene- and oxazolone-induced contact hypersensitivity in mice
Article first published online: 3 JAN 2013
DOI: 10.1111/cei.12005
© 2012 Novo Nordisk A/S Clinical and Experimental Immunology © 2012 British Society for Immunology
Additional Information
How to Cite
Christensen, A. D., Skov, S. and Haase, C. (2013), Local and systemic effects of co-stimulatory blockade using cytotoxic T lymphocyte antigen-4-immunoglobulin in dinitrofluorobenzene- and oxazolone-induced contact hypersensitivity in mice. Clinical & Experimental Immunology, 171: 220–230. doi: 10.1111/cei.12005
- †
Novo Nordisk LIFE In Vivo Pharmacology Centre (LIFEPHARM)
Publication History
- Issue published online: 3 JAN 2013
- Article first published online: 3 JAN 2013
- Accepted manuscript online: 18 OCT 2012 02:31AM EST
- Manuscript Accepted: 27 SEP 2012
Keywords:
- contact hypersensitivity;
- CTLA-4-Ig;
- immunosuppression;
- T cell activation;
- T cells
Summary
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4)-immunoglobulin (Ig) has immunosuppressive properties both in vivo and in vitro, but much is still unknown about the mechanisms by which CTLA-4-Ig exerts its immunosuppressive activities in vivo. The aim of this study was to investigate the effect of CTLA-4-Ig in a mouse model of contact hypersensitivity (CHS). The inflammatory response in the presence or absence of CTLA-4-Ig was evaluated by measuring the increase in ear thickness in sensitized animals after challenge. We observed a dose-dependent suppression of the ear swelling in both dinitrofluorobenzene (DNFB)- and oxazolone-induced CHS. The suppressive effect was still present 3 weeks after administration, even in the absence of circulating levels of CTLA-4-Ig. It was further shown that CTLA-4-Ig inhibits activation of T cells in the draining lymph node after sensitization and affects the maturation level of both dendritic cells and B cells. Furthermore, CTLA-4-Ig reduces infiltration of activated CD8+ T cells into the inflamed ear tissue and suppresses both local and systemic inflammation, as illustrated by reduced expression of cytokines and chemokines in the inflamed ear and a reduced level of acute-phase proteins in circulation. Finally, our results suggest that CTLA-4-Ig has a mainly immunosuppressive effect during the sensitization phase. We conclude that CTLA-4-Ig induces long-term immunosuppression of both DNFB- and oxazolone-induced inflammation and our data are the first to compare the effect of this compound in both DNFB- and oxazolone-induced CHS and to show that CTLA-4-Ig exerts an immunosuppressive effect on both local and systemic inflammatory mediators which is mediated principally during the sensitization phase.

1365-2249/asset/cei_left.gif?v=1&s=ffee144c532fe5e73bbb89290ba14e154b0d400b)
1365-2249/asset/cei_right.gif?v=1&s=c14d545a5215173707c8202758d5b25fd0bede44)
